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The aim of this study was to investigate the diagnostic power of CA 549, MSA and CA 15-3 in identifying breast cancer. The study
included 232 patients of which 56 were healthy, 43 had benign breast cancer and 191 with other growths. The results were obtained
usingaspeciﬁcimmunoassayandusingproducers’cutoﬀs.Thefollowingsensitivityandspeciﬁcityofmarkerswerefound:CA549
(sen.: 40%/spec.: 90%), MSA (sen.: 22%/spec.: 96%), and CA 15-3 (sen.: 33%/spec.: 86%). Ideal cut oﬀs were deﬁned with ROC
curves. A signiﬁcant correlation was found between CA 549, MSA, and CA 15-3. The combination of markers does not improve
the clinical usefulness to identify only breast cancer. Serum tumor markers are abnormally elevated in patients with breast cancer.
CA 549, MSA, CA 15-3 are useful clinical markers, good indicators of disease extent, and may have important prognostic value.
This study demonstrates the role of the tumor markers in breast cancer.
1.Introduction
An ideal cancer marker for breast cancer would be clinically
useful in many ways and, therefore, has been searched for
decades [1–4].
CA 15-3 is regarded as the most suitable cancer marker
and therefore became established in the clinical routine
worldwide. However, its sensitivity is still unsatisfactory in
the early stages of primary breast cancer [5–11].
During the last years, two new cancer markers, CA 549
andMSA(mammaryserumantigen)wereputonthemarket
[12–19].Firstanalysesshowed,insomecases,verypromising
sensitivity levels with a suﬃcient speciﬁcity.
For example CA 15-3, CA 549, and MSA belong to the
molecular family of breast mucins. CA 549 is an antigen
associated to breast cancer circulating in blood, which is de-
ﬁned by the monoclonal antibody BC4E 549 and which be-
longs to the polymorphic epithelium mucins (PEMs). CA
549 is part of the human milk fat globulin proteins
(HMFGPs).
The mammary serum antigen (MSA) is deﬁned by the
antibody 3EL.2. MSA represents a macromolecular glycolic
protein with a molecular weight over 300000.
The aim of our study was to check sensitivity and speci-
ﬁcity levels of these new markers within our group of pa-
tients. For this purpose, we determined sensitivity and speci-
ﬁcity levels for breast cancer in diﬀerent stages using various
cutoﬀs.
Furthermore, we compared our results obtained from
breast cancer patients with control groups having other dis-
eases also able to induce positive marker results.
2.MaterialsandMethods
In this study, a total of 522 serum samples were analysed.
The samples were stored deep-frozen at a temperature of
−18◦C. Among all samples tested, 232 were obtained from
breast cancer patients in diﬀerent stages, 63 were primary
breastcancerand56samplescamefromhealthywomen.The
remaining samples were obtained from the following:
43 patients with benign breast diseases;
21 patients with benign lung diseases;
27 patients with benign heart diseases;
27 patients with benign kidney diseases;
20 patients with benign liver diseases;
22 patients with lung cancer;
19 patients with stomach cancer;2 ISRN Pathology
18 patients with colon carcinoma;
37 patients with ovarian cancer.
All patients were female gender.
2.1. Methods. Serum levels of CA 549 were determined using
the Hybri-BREScan Kit from Hybritech GmbH, Cologne.
This test kit is based on the sandwich principle. Two mono-
clonal antibodies were used. One of them, BC4E 549, is an
IgGaimedatthehumanbreastcancercellularlineT417.This
antibodyislinkedtoanenzymeandwasdevelopedbyHybri-
tech Inc. (San Diego, CA, USA). The second antibody, BC4N
154, is used as a solid-phase antibody and therefore it is ﬁxed
to polystyren-globules. This antibody is an IgM deriving
from mouse and it is aimed at the human milk fat globulin
membrane.
During the test, 20uL patient serum or standard or
control substance is incubated with the antibody globules in
an horizontal mixer for an hour.
Following a ﬁrst washing, 200uL of enzyme-linked anti-
body conjugate is added. After one hour of incubation and a
second washing, a colour reaction is set oﬀ by adding 200uL
test substrate. The substrate conversion is detected colori-
metrically at 405nm and is directly proportional to the
CA 549 concentration. We used the producer’s cutoﬀ of
12,6U/mL.
With regard to the determination of the MSA serum
levels, we used an inhibition ELISA containing the murine
monoclonal antibody 3EL.2 [20].
The kit is commercially available at MEDAC company,
Hambourg.
For three hours, 25uL serum sample incubate with the
excessamountof725uLofthethinnedmonoclonalantibody
3E1.2. This monoclonal antibody is speciﬁcally aimed at
MSA and binds to MSA contained in the serum sample. The
antibody fraction which does not bind to MSA during the
ﬁrst reaction, is again incubated for 16–20 hours. In this
step, the antibody binds to MSA linked to a microtiter strip.
In the following step, 3E1.2 binds to a mouse IgM-anti-
body containing peroxidase. The result of this reaction is
the following complex: a microtiter strip-bound MSA/ 3E1.2
peroxidase marked anti-mouse IgM. The amount of this
complex is directly proportional to the colour reaction
caused by the peroxidase reaction of the ABTS (2,2 azino-
bis(ethylbenzthiazoline-6-sulfonic acid), and it is inversely
proportional to the concentration of MSA contained in the
serum sample.
By the means of a standard curve comprising six stand-
ards,everyextinctioncanbeassignedtoacertainMSAserum
level.
In accordance with producer’s recommendations, we
used a cutoﬀ 55U/mL. For the determination of CA 15-3
serum levels we used the ElektroChemiLumineszenzImm-
unoAssay “ECLIA” that is used together with ELECSYS 2010
available at Fa. ROCHE. In order to illustrate the conne
ction between sensitivity and speciﬁcity we established ROC
curves. By the means of ROC curves, sensitivity can be pre-
sented graphically in a two-dimensional way in dependence
on speciﬁcity. That means, that the sensitivity-speciﬁcity
pairs of variates are put down in a diagram in relation to
Table 1: Sensitivity and speciﬁcity of tumormarkers in breast can-
cer with cutoﬀs recommended by the producer.
CA 549 MSA CA 15-3
Sensitivity (n = 232) 40% 22% 33%
Speciﬁcity (n = 56) 90% 96% 86%
Cutoﬀ 12,6U/mL 55U/mL 25U/mL
Table 2: Sensitivity of tumor markers in breast cancer at a standar-
dized speciﬁcity of 95%.
CA 549 MSA CA 15-3
Sensitivity (n = 232) 25% 23% 19%
Speciﬁcity (n = 56) 95% 95% 95%
Cutoﬀ 15,2U/mL 48,2U/mL 35,8U/mL
increasing cut-oﬀ levels. In these curves, the statistically ideal
cutoﬀ is represented as the point, which exceeds the ﬁrst
bisector of an angle the most. This point represents the
biggest diﬀerence between healthy and ill.
3. Results
In the following, ﬁrst the results obtained from all breast car-
cinoma patients analysed are represented. Apart from the
producer’s cutoﬀs, the ideal threshold values we obtained are
shown. It is presented to what extent the markers correlate
witheachotherandwhetherthecombinationoftwomarkers
improves the clinical usefulness. Finally, the population
of the primary breast cancer patients is investigated and
the most important disease groups able to induce positive
marker results are presented.
Using the producer’s cutoﬀ, CA 549 was the most sen-
sitive marker with 40% showing a speciﬁcity still acceptable
of 90% (cutoﬀ: 12,6U/mL). In comparison, the sensitivity as
well as the speciﬁcity of CA 15-3 were about 5% lower (sen.:
33%, spec.: 86%, cutoﬀ:2 5U / m L ) .
With 22%, MSA’s sensitivity was remarkably lower com-
pared to the sensitivities of CA 549 and CA 15-3. In contrast,
MSA’s speciﬁcity was high with a value of 95% (cutoﬀ:5 5
U/mL) (Table 1).
In order to realise a more reliable comparison between
the markers, sensitivity was measured and compared at a
standardized speciﬁcity of 95%.
As a result, CA 549’s sensitivity (25%) was similar to the
one of MSA (23%) and slightly higher than the sensitivity of
CA 15-3 (19%) (Table 2).
At the same time, it is possible to check whether the
cutoﬀs recommended by the producer lead to an ideal sepa-
ration between healthy women and women suﬀering from
breast cancer in our study too. For CA 15-3, we obtained the
best distinction between healthy an ill at a cut-oﬀ 25U/mL.
In this case, sensitivity is 33% and speciﬁcity 86%. With
regard to MSA, the statistically ideal cutoﬀ in our patient
population lies at a value of 50U/mL whilst sensitivity is
30% and speciﬁcity 89%. When it comes to CA 549, its ideal
threshold value is 9U/mL. In this case sensitivity is 59%
whilst speciﬁcity is relatively low with 82%.ISRN Pathology 3
Table 3: Sensitivity of tumor markers in primary breast cancer in
stages T1– T4.
CA 549 MSA CA 15-3
Sensitivity (n = 63) 33% 18% 35%
Sen. T1-Stage (n = 26) 35% 8% 15%
Sen. T2-Stage (n = 27) 33% 22% 48%
Sen. T3-Stage (n = 4) 25% 25% 0%
Sen. T4-Stage (n = 6) 33% 33% 83%
Speciﬁcity (n = 56) 90% 96% 89%
Cutoﬀ 12,6U/mL 55U/mL 25U/mL
In order to check whether one of these cancer markers
is particularly suitable for early diagnosis, we analysed the
patientpopulationwithprimarybreastcancerindependence
on the diﬀerent stages. With reference to the overall pop-
ulation with primary breast cancer, CA 15-3 achieved best
sensitivity (35%) when using the cutoﬀ recommended by the
producer. Sensitivity for stage T1 was 8% and stage T2 22%
(Table 3).
In order to obtain a more reliable comparability, we used
a uniform speciﬁcity of 95% when analyzing the speciﬁcity
of the three cancer markers in our patient population with
primary breast cancer. In this case, the total sensitivity of
MSA was best (18%), however, in stage T1 sensitivity only
was 8% and in stage T2 22%. Total sensitivity of CA 549 was
11% (T1 = 8%, T2 = 19%). Total sensitivity of CA 15-3 was
14% (T1 = 4%, T2 = 22%).
In order to ﬁnd out, whether using only one marker out
of the group of polymorphic epithelium mucins in the clini-
cal routine is suﬃcient, we investigated the expressiveness of
every single marker.
As a result, the correlation coeﬃcient between MSA and
CA 549 was 0,73. We found the same result for MSA and CA
15-3. CA 15-3 and CA 549 correlated best showing a cor-
relation coeﬃcient of 0,89.
Therefore,weobtainedaquitesatisfactorycorrelationfor
the biological systems between the members of this molecu-
lar family,CA 15-3, MSA, andCA 549. In order to ﬁndout to
what extent the simultaneous use of diﬀerent cancer markers
in view of the quite high correlation coeﬃciencies is suitable,
we combined the markers. The combination of two markers
resulted in an improved sensitivity. When combining CA 15-
3 and CA 549, sensitivity improved from 40% to 49% at
a speciﬁcity of 77%. Sensitivity could be raised from 40%
to 53% when MSA, CA 15-3, and CA 549 were combined
whilst speciﬁcity was 73%. The combination of the markers
CA 549 and MSA showed a sensitivity of 44% (spec.: 82%)
and MSA and CA 15-3 together also achieved a sensitivity of
44% (spec.: 79%). All these results were obtained using the
producer’s cutoﬀ (Table 4).
First, the rate of false positive marker results within the
healthy control group is detected for the cancer markers CA
549 and MSA. These are compared to the results obtained
from control groups suﬀering from other diseases, that are
alsoabletoinducepositivemarkerresults.Withinthehealthy
controlgroup, 11% werepositive forCA549. Incontrast,CA
Table 4: The combination of tumor markers with the sensitivity
and speciﬁcity.
Tumor marker combination Sensitivity Speciﬁcity
CA 549 + MSA 44% 82%
CA 549 + CA 15-3 49% 77%
MSA + CA 15-3 44% 79%
MSA + CA 15-3 + CA 549 53% 73
549washighlyelevatedinpatientswithhepatitis(62%),with
ovarian cancer (39%) as well as renal diseases (48%).
WithregardtoMSA,resultsforthehealthycontrolpopu-
lation were even better. In this case, only 4% were MSA posi-
tive, whilst MSA was elevated in 38% in patients with hepa-
titis, 52% in patients with renal disease, 35% in patients with
ovarian carcinoma, with lung carcinoma in 32%, 29% in pa-
tients with other lung diseases, and 26% in patients with
heart diseases.
4. Discussion
Oneofthemainrequestsforanideal cancermarkerisits sui-
tability for preclinical screening. Therefore, a prerequisite
would be a high sensitivity as well as speciﬁcity with respect
to the detection of primary breast cancer. Using a speciﬁcity
level of 95%, results for the sensitivity of CA 15-3 for breast
cancer in diﬀerent stages varied from 5% to 60%, depending
on the work group. In our study, we were not able to conﬁrm
the extraordinary positive results obtained in some cases. As
far as the sensitivity of the marker CA 549 is concerned, the
data available also diﬀers enormously. In diﬀerent stages of
breast cancer, between 12% and 77% are tested positive for
CA 549.
According to our study, CA 549 showed the best sensitiv-
ity among all markers, but its speciﬁcity was low. With ref-
erence to MSA’s sensitivity, literature shows results between
34% and 79% (spec.: 95%). In our study, its sensitivity was
noticeably lower. According to our results, the usefulness
of the cancer markers available is still not satisfactory with
respect to primary breast cancer. In particular, this is the case
in the early stages of this disease.
In the literature, CA 15-3’s sensitivity ranges from 3% to
2 5 %f o rT 1b r e a s tc a n c e r .O u rr e s u l t sf o rT 1b r e a s tc a n c e r
also lie within this scope. With regard to MSA’s sensitivity,
data from various authors ﬂuctuate between 8% and 50%.
Our own results conﬁrm these rather reserved information.
Sensitivity for CA 549 for T1 breast cancer stages varied from
3% to15% in the literature. With a sensitivity of 35% for this
patient group, our result was quite positive. However, this
result is put into perspective by the fact of an unsatisfactory
speciﬁcity and the small group of patients analysed.
Recapitulatory, we support the opinion of Stenmans and
Haikkinens that there is no cancer marker available so far,
that shows a suﬃcient sensitivity in the early diagnosis of
breast cancer. This fact is not changed noticeably when
adding the new markers CA 549 and MSA.
A possibility to improve the clinical usefulness might be
thecombinationofnoncorrelatingcancermarkers.However,4 ISRN Pathology
CA549,MSA,andCA15-3belongtothemolecularfamilyof
breast mucins. The results of several work groups conﬁrmed
a good correlation. Our results corroborated this [21–23].
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